Compare Gilead Sciences, Inc. (GILD) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs HubSpot Inc — how do they compare? Gilead Sciences, Inc. trades at $133.05 (market cap $163.51B), while HubSpot Inc trades at $218.74 (market cap $11.02B). The key difference: Gilead Sciences, Inc. is far larger — about 14.8× HubSpot Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| GILD | HUBS | |
|---|---|---|
Market Cap | $163.51B | $11.02B |
Sector | Health | Technology |
52-Week High | $155.80 | $560.90 |
52-Week Low | $108.22 | $170.39 |
Enterprise Value | $178.05B | $9.58B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
HubSpot (HUBS) trades at $209.68, down 3.64% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $268.75. The company reported Q1 2026 EPS of $2.72, beating estimates, and shows strong revenue growth, reaching $3.13B in 2025. Positive sentiment is driven by AI integration and customer expansion, with 80.85% of analysts rating it a Buy.
The outlook for HUBS is positive, supported by robust revenue growth, expanding AI capabilities, and consistent earnings beats. Key risks include high valuation multiples and competitive pressures in the CRM space. Investors should monitor execution on AI monetization and margin improvement for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
